Some producers focus on saving pigs. Others on practices that save time. And to others, it's all about money and the bottom line. While what matters most may vary by producer, choosing a respiratory disease treatment that helps save pigs, time and money is an important component of an anti-infective programme.

"Selecting the right anti-infective programme for your herd's situation is important," says Michael Senn, DVM, manager, technical services at Pfizer Animal Health. "It's critical to get an accurate diagnosis, and support the effective and judicious use of antibiotics in the livestock industry. At Pfizer Animal Health, we work hard to provide diagnostic support for our customers through funding and veterinary involvement."

Save Pigs. Save Time. Save Money.

As part of Pfizer Animal Health's comprehensive anti-infective portfolio, DRAXXIN® (tulathromycin) Injectable Solution helps producers save pigs, time and money.

"With just one dose, DRAXXIN fights five of the most common bacterial respiratory pathogens," Dr Senn says. "It provides at least nine full days¹ of activity to ensure growing pigs have every chance to be on the road to recovery."

One convenient treatment minimizes labor and handling stress while treating the five major bacterial causes of swine respiratory disease (SRD):

• Actinobacillus pleuropneumoniae

DRAXXIN controls SRD in groups of pigs where SRD has been diagnosed and is associated with:

• Actinobacillus pleuropneumoniae

In addition to fighting SRD, DRAXXIN has been shown to reduce mortality² - which can lead to more high-value pigs² going to market.

To learn more about DRAXXIN saving pigs, time and money, please click here.

The pre-slaughter withdrawal time for DRAXXIN in swine is five days. DRAXXIN should not be used in animals known to be hypersensitive to the product.

1. Benchaoui, HA, Nowakowski M, Sherington J, Rowan TF, Sunderland SJ. Pharmacokinetics and lung tissue concentrations of tulathromycin in swine. J Vet Pharm Therapeutics 2004; 27:203-210.
2. Data on file, Study Report No. 1123R-60-07-283, Pfizer Inc.

Further Reading

-

Find out more information on respiratory diseases by clicking here.